Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,227.52
(
-1.05%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 49502

Sunday, 11/23/2008 8:03:23 PM

Sunday, November 23, 2008 8:03:23 PM

Post# of 257580
Rep. Dingell and FoB Legislation

The recently announced ouster of Rep. Dingell from the chair of the House Energy and Commerce Committee is a positive development for biotech companies seeking to capitalize on FoB’s. Dingell was one of the main impediments to the enactment of FoB legislation for reasons that have never been clear to me.

As an aside, Dingell has served in the House of Representatives for 54 years (!), longer than all but one person in the history of the USA.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today